Supplementary table: Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: Model inputs for efficacy.Aim: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Materials & methods: Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Results: UsingMedicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/qualityadjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. Conclusion: OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.

本数据集为发表于《比较疗效研究杂志》的论文《从美国商业和支付者视角看过度活动膀胱治疗的经济效益》的同行评审补充材料。补充表1：疗效模型输入。目标：通过先前发表的马尔可夫模型，将治疗选项（抗胆碱能药物、β3-肾上腺素受体激动剂、奥那布斯汀肉毒毒素A、骶神经刺激和经皮胫骨刺激[后两者包括新型可充电神经刺激器]）在管理过度活动膀胱（OAB）方面的成本效益与最佳支持治疗（BSC）进行比较。材料与方法：在15年的时间框架内评估成本效益，并使用2年和5年的时间框架进行敏感性分析。中断率、资源利用和成本来源于已发表的文献。结果：在15年的时间段内，使用医疗保险和商业成本，奥那布斯汀肉毒毒素A 100U相对于BSC的增量成本效益比（ICER）分别为39,591美元/质量调整生命年（QALY）和42,255美元/QALY，这是所有评估治疗中最低的ICER。在2年和5年的时间框架下的敏感性分析也表明，奥那布斯汀肉毒毒素A相对于BSC是所有评估治疗中最具成本效益的。结论：奥那布斯汀肉毒毒素A 100U目前是治疗OAB最具成本效益的治疗方案。